Celldex Therapeutics Q3 2026 EPS Tops Estimates at -$0.96, but Revenue Misses at $400K
Revenue of $400K vs. $723K expected and adjusted EPS of -$0.96 vs. -$1.02.
Celldex Therapeutics (CLDX) posted mixed third-quarter 2026 results, with adjusted EPS above the estimate and revenue below it. Revenue was $400 thousand below the $723 thousand estimate, and adjusted EPS was -$0.96, up 5.0% from a year earlier, above the -$1.02 estimate.
Q3 2026 scorecard
| Parameters | Expected | Actual | Beat/Miss |
|---|---|---|---|
| Adjusted EPS | -$1.02 | -$0.96 | Beat by 5.9% |
| Revenue | $723K | $400K | Miss by 45% |
| Change | QoQ |
|---|---|
| Adjusted EPS | ▼ 2.1% |
| Revenue | ▲ 1718% |
By our calculation, revenue was $323 thousand below the estimate and adjusted EPS was $0.06 above it. The QoQ column compares with the previous quarter's revenue of $22 thousand and adjusted EPS of -$0.94.
Track record
- EPS record. Adjusted EPS beat the estimate in 4 of the last 8 reports, including this one.
- Revenue record. Revenue beat the estimate in 1 of the last 7 reports.
- Revenue trend. Revenue over the last 4 reports, oldest first: $100 thousand, $15 thousand, $22 thousand and $400 thousand.
What to watch
- Next-quarter estimates. Consensus calls for EPS of -$1.02 and revenue of $1.2 million next quarter, based on 7 analysts.
- Estimate record. Whether Celldex Therapeutics extends a record of beating EPS estimates in 4 of its last 8 reports.
- Sequential trend. Whether revenue builds on its 1718% increase from the previous quarter.
- Related coverage. See our reports on Interface, Brighthouse Financial, Brookfield Renewable and Aura Minerals.
Sources: Results are from Celldex Therapeutics's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Celldex Therapeutics's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.
Readers also read
Interface Matches Q3 2026 Estimates as Revenue Rises 3.6% to $377.61M
EarningsBrighthouse Financial Q3 2026 EPS Tops Estimates at $9.12, but Revenue Misses at $2.05B
EarningsBrookfield Renewable Q3 2026 EPS Tops Estimates at $17.87, but Revenue Misses at $1.60B
EarningsAura Minerals Q3 2026 Revenue Tops Estimates at $386.0M, but EPS Misses at $1.43
MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.